ノボ・ノルディスク

 NVOのチャート


 NVOの企業情報

symbol NVO
会社名 Novo-Nordisk AS (ノボ・ノルディスク)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 ノボ・ノルディスク(Novo Nordisk A/S)は医薬品の発見・開発・製造・マーケティングに従事するヘルスケア会社である。同社は糖尿病・肥満治療とバイオ医薬品という2つの事業区分により構成される。糖尿病・肥満治療事業はインスリン、グルカゴン様ペプチド-1(GLP-1)、グルカゴン、タンパク質関連運搬試薬とニードル等のタンパク質関連製品及び経口抗糖尿病薬等をカバーする。バイオ医薬品事業は血友病、成長ホルモン療法、ホルモン補充療法及び他の治療領域向けの製品を提供する。同社は次世代インスリンと新型インスリンポートフォリオを含む各種糖尿病製品を提供する。同社はデンマーク、イタリア、カナダにおいて肥満の治療用製品であるSaxendaを提供する。他の製品はXultophy、Semaglutide (NN9535)、超速効型インスリン・アスパルト製剤(NN1218)、N9-GP (NN7999)、N8-GP (NN7088)及びNN8640週1回ヒト成長ホルモンを含む。  ノボ・ノルディスクは製薬会社。糖尿病治療、血友病治療、成長ホルモン療法、ホルモン補充療法の領域で製品を提供。主要の糖尿病領域では、インスリン製剤、GLP-1受容体作動薬、経口抗糖尿病薬、肥満治療薬を「ノボロッグ」、「ノボラピッド」、「ノボミックス」、「プラディン」、「ノボノ―ム」のブランド名で提供。世界180カ国以上で製品を販売。  
本社所在地 Novo Alle Bagsvaerd DK-2880 DNK
代表者氏名 Helge Lund
代表者役職名 Independent Chairman of the Board
電話番号 +45 44-44-8888
設立年月日 11628
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 42076人
url www.novonordisk.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 7670.26800
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 97105.77000
売上高 (百万ドル) 16802.29000
企業価値(EV) (百万ドル) 94833.58229
当期純利益 (百万ドル) 5803.74700
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Novo Nordisk A/S (ADR) revenues increased less than 1% to DKR111.83B. Net income increased 1% to DKR38.63B. Revenues reflect Region China segment increase of 5% to DKR11.29B Europe segment increase of 2% to DKR21.68B Latin America segment increase of 8% to DKR4.01B also reflect USA segment decrease of 2% to DKR54.49B Japan_Korea segment decrease of 5% to DKR5.8B.

 NVOのテクニカル分析


 NVOのニュース

   No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide  2021/04/21 17:53:05 Benzinga
Novo Nordisk A/S (NYSE: NVO ) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg. The company will launch the trial in the second half of … Full story available on Benzinga.com
   Novo Nordisk macht das, was Warren Buffett gefällt! Von The Motley Fool  2021/04/13 00:00:00 Investing.com Germany
Novo Nordisk macht das, was Warren Buffett gefällt!
   Marc Andreessen says he found the 'silver bullet' for weight loss, and he's been using the drug for 40 days without side effects  2021/03/26 16:40:14 Business Insider
Summary List Placement Marc Andreessen is trying to eat right in lockdown, just like millions of people around the world. The tech investor says he reads dietary guidance from experts — vegetables, good; vegetable oil , maybe bad — but it's hard keep up. "I'm trying to do my best but then I'm hungry all the time. You know, it's like, f--k. I got to concentrate on my work and I want to spend time with my kids and I don't want to be hungry all the time," Andreessen said on a podcast . Now, the six-foot-five venture capitalist says he's found a "miracle drug" and he sees it as a cure for the obesity epidemic. On the " Lindy Talk " podcast in early March, Andreessen told host Paul Skallas that he had been taking a version of semaglutide, a drug used to treat type 2 diabetes, for about 40 days and that it stopped his hunger pangs. The drug semaglutide was found in one recent study to help people with obesity lose more weight than any other medicine on the market, although it's only approved by regulators for use in adults with type 2 diabetes. "I've been taking this now for like 40 days, and I gotta tell you, it's freaking amazing," Andreessen said on the podcast. "It's just like absolutely amazing.
   Novo Nordisk and TetraScience partner on a cloud-based instrument data platform  2021/03/23 11:50:00 PR Newswire
BAGSVÆRD, Denmark and BOSTON, March 23, 2021 /PRNewswire/ -- Novo Nordisk A/S, a leading global healthcare company, and TetraScience, the leading global Life Sciences R&D Data Cloud, announce a new partnership to design a cloud-based instrument data platform for drug R&D, built natively…
   Reproductive Hormone Market Next Big Thing | Major Giants AbbVie Inc., Allergan plc, Pfizer Inc., Novo Nordisk A/S, Endo Pharmaceuticals Inc  2021/03/23 10:25:38 OpenPR
CMI Published Latest Global Reproductive Hormone Market Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast. Revenue for Reproductive Hormone Market has grown substantially over the seven years to 2020 as a result
   Novo Nordisk and TetraScience partner on a cloud-based instrument data platform  2021/03/23 11:50:00 PR Newswire
BAGSVÆRD, Denmark and BOSTON, March 23, 2021 /PRNewswire/ -- Novo Nordisk A/S, a leading global healthcare company, and TetraScience, the leading global Life Sciences R&D Data Cloud, announce a new partnership to design a cloud-based instrument data platform for drug R&D, built natively…
   Reproductive Hormone Market Next Big Thing | Major Giants AbbVie Inc., Allergan plc, Pfizer Inc., Novo Nordisk A/S, Endo Pharmaceuticals Inc  2021/03/23 10:25:38 OpenPR
CMI Published Latest Global Reproductive Hormone Market Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast. Revenue for Reproductive Hormone Market has grown substantially over the seven years to 2020 as a result
   Ildsjælen bag verdens tredjestørste fond takker af med en salut til politikerne: Find flere penge til universiteterne  2021/03/20 17:14:00 Berlingske
Birgitte Nauntofte har i mere end et årti være ildsjælen bag Novo Nordisk Fondens udvikling fra en mindre, ukendt fond til en af verdens største. Fonden uddeler milliarder til dansk forskning og er med til at sikre, at store virksomheder som Novo Nordisk og Novozymes bliver i Danmark. Men hun savner en hjælpende hånd fra politikerne.
   U.S. Safety Needles Market Emerging Growth By Top Players Medtronic Plc., Becton, Dickinson and Company, Boston Scientific Corporation, Smith Medical, Abbott Laboratories, Argon Medical Devices, Inc., Novo Nordisk A/S  2021/03/19 07:51:08 OpenPR
Safety needles are designed for delivering drugs and collecting fluids from the body with safety features to avoid needle stick injuries. There are various types of safety needles such as fine aspirating needles, biopsy needles, hypodermic needles, pen needles, suture
   Therapeutic Proteins and Oral Vaccines Market Emerging Growth By Top Players Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc  2021/03/19 07:44:47 OpenPR
Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease. They can also augment the body’s supply of a beneficial protein to help reduce the impact of disease or chemotherapy. Genetically engineered
   Novo-boss slingrer i vaccinevalsen med statsministeren – men Mette F. får nok sin vilje  2021/03/17 06:25:00 Berlingske
Vi havde næppe vacciner mod hverken corona, ebola eller kopper, hvis ikke regeringerne i USA og Tyskland havde pumpet milliarder i udvikling og produktion. Et godt gæt er, at Novo Nordisk Fonden leverer en pose penge til en dansk coronasatsning.
   Regeringen drøfter dansk vaccineproduktion med stenrig fond  2021/03/15 09:15:00 Berlingske
Den danske regering er lige nu i dialog om muligheden for at etablere produktion af vacciner på dansk grund med landets største fond, Novo Nordisk Fonden, der råder over en formue på over 400 milliarder kroner. Det oplyser erhvervsministeriet i en mail til Berlingske. Novo Nordisk Fonden bekræfter, at der er »drøftelser med regeringen om mulighederne for at etablere en vaccineproduktion i Danmark«.
   Pen Needles Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2028 | Dickinson and Company, Novo Nordisk, Ulticare, Ypsomed Holding AG, B. Braun Melsungen AG  2021/03/12 15:17:09 OpenPR
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Pen Needles Market: Global Opportunity Analysis and Industry Forecast 2021-2028’. The Pen Needles Market is expected to witness growth in upcoming years due to factors such as increase in target patient
   Top Insights Of Smart Insulin Pens Market Report Covered By TBRC Market Research With Major Key Players: Eli Lilly and Company, Novo Nordisk A/S  2021/03/11 05:32:18 OpenPR
New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The global smart insulin pens market is expected to grow from $75.8 million in 2019 and
   Novo-fonden vil gøre dansk landbrug klimasmart  2021/03/04 17:25:00 Berlingske
Novo Nordisk Fonden investerer trecifrede millionbeløb i forskning i klimaløsninger til dansk landbrug. Men det er kun plantedriften, der får glæde af pengene. Fonden har truffet en principbeslutning om ikke at give penge til direkte forskning i kødproduktion.

 関連キーワード  (医薬品 米国株 ノボ・ノルディスク NVO )

 twitter  (公式ツイッターやCEOツイッターなど)